How much funding has SAB Biotherapeutics, Inc. raised?

SAB Biotherapeutics, Inc. has raised $131.1M in total funding, most recently a Growth Equity round.

When was SAB Biotherapeutics, Inc. founded?

SAB Biotherapeutics, Inc. was founded in 2016.

Where is SAB Biotherapeutics, Inc. headquartered?

SAB Biotherapeutics, Inc. is headquartered in Sioux Falls, South Dakota, United States.

What industry is SAB Biotherapeutics, Inc. in?

SAB Biotherapeutics, Inc. operates in Biotech, Healthcare.

How many employees does SAB Biotherapeutics, Inc. have?

SAB Biotherapeutics, Inc. has 11-50 employees.

SAB Biotherapeutics, Inc.

Q: Who are SAB Biotherapeutics, Inc.'s investors?

SAB Biotherapeutics, Inc.'s investors include Sanofi Ventures, RA Capital Management, Commodore Capital.

Home - SAB BIO

Sioux Falls, United States · Founded 2016 · $131.1M raised

Biotech

Healthcare

Headquarters: Sioux Falls, South Dakota
Employees: 11–50
Founded: 2016
Business Model: B2B

Website: sabbiotherapeutics.com
Total Funding: $131.1M
Last Round: $130.0M Growth EquityOct 2023
Rounds: 2

About

SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing disease-modifying immunotherapies for autoimmune diseases. Its lead asset, SAB-142, targets Type 1 Diabetes by addressing the underlying autoimmune cause — preserving beta cell function rather than managing symptoms. Founded in 2016 in Sioux Falls, South Dakota, SAB has received SBIR/STTR awards from the Department of Health and Human Services.

Summary

SAB Biotherapeutics, Inc. is a Biotech company based in Sioux Falls, United States, founded in 2016. It has raised $131.1M in total across 2 rounds, most recently a $130.0M Growth Equity round in Oct 2023. Investors include Sanofi Ventures, RA Capital Management and Commodore Capital.

LinkedIn X (Twitter)